Literature DB >> 11073270

Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.

M Schömig1, E Ritz.   

Abstract

Chronic renal failure is characterized by diminished synthesis of, and resistance to, the active vitamin D metabolite 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3, calcitriol). Calcitriol results from the biotransformation of the precursor 25-hydroxy-vitamin D3 (25(OH)D3) to 1,25(OH)2D3. 25(OH)D3 is synthesized in the liver, and 1alpha-hydroxylase, the rate-limiting enzyme for its biotransformation into the most active metabolite, 1,25(OH)2D3, is located in the kidney. The regulation of 1alpha-hydroxylase in renal failure is not well known. Recent work indicates that, in contrast to previous opinion, 1alpha-hydroxylase is predominantly expressed not in the proximal tubule but in the distal tubule [1]. In vivo, the main stimulatory signal is presumably parathyroid hormone (PTH) and the main inhibitory signal hyperphosphataemia. Both signals are altered in renal failure. There is also evidence that the renal 1alpha-hydroxylase becomes substrate-dependent in patients with renal failure. This means that a higher concentration of the precursor 25(OH)2D3 will result in a higher rate of transformation into the active metabolite 1,25(OH)2D3 in renal patients. Calcitriol is not exclusively synthesized in the kidney, but may also be synthesized in extra-renal tissues, e.g. activated monocytes/macrophages [2], particularly in granuloma [3] as shown by anephric uraemic patients who develop hypercalcaemia and elevated calcitriol concentrations when sarcoidosis [4] or tuberculosis [5] supervenes. On the other hand, calcitriol is less effective in uraemia. This may be to some extent due to diminished expression of vitamin D receptors [6], particularly in parathyroid glands when they undergo nodular transformation [7], but there may also be resistance to calcitriol at the post-receptor level [8]. In a series of elegant experiments [9,10], calcitriol resistance has been related to disturbed genomic effects of active vitamin D because the interaction of the vitamin D receptor ligand complex with vitamin D-responsive elements (VDREs) upstream of vitamin D-regulated genes was disturbed by the action of low molecular weight substances in uraemia, which have not been completely characterized. The role of genetically determined polymorphisms of the vitamin D receptor in the genesis of disturbed calcium metabolism of renal failure is currently unclear.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11073270     DOI: 10.1093/ndt/15.suppl_5.18

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

Review 1.  Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.

Authors:  Hubertus Rosery; Rito Bergemann; Steven E Marx; Axel Boehnke; Joel Melnick; Raimund Sterz; Laura Williams
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 2.  Vitamin D and Anaesthesia.

Authors:  Ebru Biricik; Yasemin Güneş
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-03-03

3.  Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate.

Authors:  Paul Muntner; Tiffany M Jones; Amanda D Hyre; Michal L Melamed; Arnold Alper; Paolo Raggi; Mary B Leonard
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-19       Impact factor: 8.237

4.  Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism.

Authors:  Kiyoko Hosaka; Junichiro James Kazama; Suguru Yamamoto; Yumi Ito; Noriaki Iino; Hiroki Maruyama; Akihiko Saito; Ichiei Narita; Fumitake Gejyo
Journal:  J Bone Miner Metab       Date:  2008-02-27       Impact factor: 2.626

Review 5.  Immune Dysfunction in Uremia 2020.

Authors:  Gerald Cohen
Journal:  Toxins (Basel)       Date:  2020-07-05       Impact factor: 4.546

Review 6.  Immune dysfunction in uremia—an update.

Authors:  Gerald Cohen; Walter H Hörl
Journal:  Toxins (Basel)       Date:  2012-10-24       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.